• Latest
    • Big pharma
    • Biotechnology
    • CRISPR
    • Generics
    • Unified Patent Court
  • Regions
    • Americas
    • Europe
    • Asia
    • Asia-Pacific
  • Careers
  • Events
    • Conferences
    • Conference Videos
    • Webinars
  • Directory
  • Magazines
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate
18 March 2021

Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate

The Patent Trial and Appeal Board is an important forum for determining a US patent’s validity. Since 2012, when inter partes review of US patents began, the PTAB’s cancellation rate for challenged patents has varied dramatically.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk




Editor's picks

Novartis and Eli Lilly sign separate $1.9bn novel drug deals
Biotechnology
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026

Editor's picks

Biotechnology
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

More features

Merck KGaA agrees $11.3bn deal in major life sciences expansion
Pfizer’s US Paxlovid patent fight turns on a single error
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
Novo secures website blocking to tackle fake weight-loss drugs
GLP-1 patents and Africa: The COVID-19 lessons we still have not learned
Cooley Asia transactions duo make rival firm move
Insilico lands potential $2.5bn AI biotech partnership
‘Blatant imitation’: Indian court blocks copycat pharma branding

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin